Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tarix Pharmaceuticals Ltd.
Cambridge, Massachusetts, United Statestarixpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company conducted Phase 2 clinical trials for TXA127 in various indications including peripheral blood stem cell engraftment and cord blood transplantation. Their lead product TXA127 received Fast Track Designation from the FDA for Duchenne Muscular Dystrophy.
- Therapeutic areas
- HematologyImmunologyRare DiseasesNeurology
- Modalities
- Peptide-based therapies
- Industry
- Biotech
02
Partnerships
Unigene Laboratories (licensing agreement for Peptelligence technology)
Beyond the preview
Go deeper on Tarix Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarix Pharmaceuticals Ltd..